Robinson M R, Denis L, Mahler C, Walker K, Stitch R, Lunglmayr G
Eur J Surg Oncol. 1985 Jun;11(2):159-65.
The luteinizing hormone releasing hormone, Zoladex, has been used in three centres, Pontefract, Antwerp and Mistelbach, to treat carcinoma of the prostate. An initial protocol using a soluble daily injection has been followed by a second study employing a monthly administered depot preparation. After an initial stimulation it has been shown that both daily and monthly injections reduce plasma testosterone to castrate levels. Circulating luteinizing hormone levels are also initially stimulated and then suppressed. Treatment toxicity has been minimal and in these short term studies reduction of acid phosphatase and subjective and objective tumour responses have been similar to those expected from effective hormonal therapy of prostatic cancer.
促黄体生成激素释放激素（zoladex）已在庞特弗拉克特、安特卫普和米斯特尔巴赫的三个中心用于治疗前列腺癌。最初采用每日可溶性注射的方案，随后进行了第二项研究，采用每月给药一次的长效制剂。初步刺激后发现，每日和每月注射均能将血浆睾酮水平降至去势水平。循环促黄体生成激素水平最初也会受到刺激，然后被抑制。治疗毒性极小，在这些短期研究中，酸性磷酸酶的降低以及主观和客观的肿瘤反应与前列腺癌有效激素治疗预期的反应相似。
